{"id":"W2514766623","doi":"10.2337/dc16-0917","title":"Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial","year":2016,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Endocrinology; Basal insulin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002101377,0.001718313,0.003148057,0.0004899743,0.0002950263,0.001064013,0.001025874,0.001757067,0.004924814],"category_scores_gemma":[0.00176406,0.0006720175,0.002146302,0.0003724647,0.0009950977,0.00110705,0.0005312195,0.002598738,0.0005951932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000718322,"about_ca_system_score_gemma":0.0007369007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007006894,"about_ca_topic_score_gemma":0.001141297,"domain_scores_codex":[0.999073,0.000534487,0.00006748187,0.0001518102,0.00006794857,0.0001050835],"domain_scores_gemma":[0.9990091,0.0002985865,0.0003029896,0.00006971294,0.00004278871,0.0002767696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9916727,0.001878301,0.0004048059,0.0002556405,0.0004857734,0.00001140006,0.000009849386,0.0001054485,0.0006776755,0.00002555799,0.0001018164,0.004371058],"study_design_scores_gemma":[0.9366504,0.05998287,0.001381164,0.00003974406,0.0009925857,0.00001971427,0.00001773429,0.0003169393,0.0002975161,0.00008509132,0.0002060054,0.00001022447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896762,0.005696154,0.000412396,0.0004528857,0.0004048065,0.001521747,0.0004774093,0.00007163506,0.001286842],"genre_scores_gemma":[0.9916112,0.002447632,0.001133104,0.0007464745,0.0004304873,0.001594372,0.0005513415,0.00001551627,0.001469765],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004924814,"threshold_uncertainty_score":0.01647508,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02269637888175718,"score_gpt":0.2615490002325614,"score_spread":0.2388526213508043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}